HE
HESG.US Health Sciences Gr
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -9.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2012.
Is HESG.US undervalued?
Graham numberThe Graham number of Health Sciences Gr cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Health Sciences Gr fundamental analysis
No fundamental analysis for Health Sciences Gr yet.
Health Sciences Gr stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Health Sciences Gr
Health Sciences Group, Inc., through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system. The company also offers Aplevia, …
Full company profileHealth Sciences Gr financial statements
Health Sciences Gr annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 342K | 5.54M | 5.37M | 67.2K | 60.1K | 174K | 197K | 358K |
| Gross Profit | - | 83.0K | 1.49M | 998K | 46.7K | 22.9K | 45.8K | 66.0K | 25.2K |
| Operating Income | -34.3K | -825K | -4.08M | -3.80M | -4.55M | -7.48M | -99.5K | -66.4K | -54.5K |
| EBITDA | -32.8K | -793K | -3.78M | -2.32M | -3.29M | -4.97M | - | - | -44.7K |
| Net Income | -34.2K | -735K | -4.28M | -7.42M | -10.5M | -5.75M | -99.5K | -66.4K | -54.5K |
| EPS | -0.02 | -0.22 | -0.73 | -0.67 | -0.74 | -0.23 | - | - | -0.03 |
| Balance Sheet | |||||||||
| Total Assets | 34.9K | 6.27M | 5.97M | 10.9M | 4.40M | 4.16M | 1.31M | 1.18M | 1.03M |
| Total Liabilities | 13.0K | 1.28M | 1.50M | 9.92M | 10.5M | 9.07M | 672K | 735K | 436K |
| Shareholders' Equity | 21.9K | 4.98M | 4.47M | 978K | -6.12M | -4.91M | 638K | 444K | 596K |
| Cash & Short-term Investments | 5.31K | - | 169K | 121K | 241K | 21.3K | 2.34K | 1.77K | 1.38K |
| Total Debt | 8.00K | 655K | 480K | 872K | 1.04M | 335K | - | - | 320K |
| Cash Flow | |||||||||
| Operating Cash Flow | -9.73K | -350K | -596K | -1.14M | -1.05M | -3.74M | 1.18K | 578.00 | 42.0K |
| Capital Expenditure | 5.46K | 20.4K | 19.4K | 94.5K | 2.81K | 360K | 0.00 | 0.00 | 2.00 |
| Free Cash Flow | -15.2K | -370K | -615K | -1.24M | -1.06M | -4.10M | - | - | 42.0K |
| Ratios | |||||||||
| ROE | -156.5% | -14.7% | -95.8% | -758.3% | - | - | -15.6% | -14.9% | -9.1% |
| ROA | -98.2% | -11.7% | -71.7% | -68.1% | -237.5% | -138.4% | -7.6% | -5.6% | -5.3% |
| Net Profit Margin | - | -215.0% | -77.4% | -138.3% | -15,552.6% | -9,560.7% | -57.1% | -33.6% | -15.2% |
| Debt to Equity | 0.37x | 0.13x | 0.11x | 0.89x | - | - | - | - | 0.54x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Health Sciences Gr dividends
Health Sciences Gr has not paid dividends in the last 9 fiscal years.
Who owns Health Sciences Gr
Ownership data of Health Sciences Gr is not available yet.
Health Sciences Gr company profile
- Company name
- Health Sciences Gr
- Ticker
- HESG.US
- Exchange
- USA Stocks
- Listed since
- Aug 3, 2001
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 2
- Fiscal year end
- December
- Address
- 2549 Eastbluff Drive, Newport Beach, CA, United States, 92660
- Website
- -
About Health Sciences Gr
Health Sciences Group, Inc., through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system. The company also offers Aplevia, an antioxidant derived from apple peels; and Edible Sponges, an open-cell hydrocolloid product. It sells its products primarily through mass market retailers, such as mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners, and other media. Health Sciences Group was founded in 1996 as Centurion Properties Development Corporation and changed its name to iGoHealthy.com in 2000. It changed its name to Health Sciences Group, Inc. in 2001. The company is based in Newport Beach, California.
Health Sciences Gr management
3- Mr. Thomas GaffneyChief Executive Officer and President
- Mr. Raymond C. SignoreDirector of Sales & Marketing
- Dr. Fred Aserati Ph.D.Vice President of Business Development